EUVIMEDEUVIMED entdecken
Crossref

Reprogramming lysosomal–purinergic crosstalk governs the synergistic attenuation of NLRP3 inflammasome activation by cyclodextrin–P2X7 blockade in diabetic rats

Elsayed A Elmorsy, Manal Mohamed Hatem, Hamad Alsaykhan, Abdulaziz A Alsalloom, Mostafa M Khodeir, Mohammed Alorini, Rabab S Hamad, Alshaimaa A Farrag, Mohamed A M Ali, Norah Suliman Alsoqih, Omar Almansour, Mariam S Alharbi und 5 weitere

European Journal of Pharmacology · 2026

DOI: 10.1016/j.ejphar.2026.178602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Elsayed A Elmorsy und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, 51452, Saudi Arabia; Department of Clinical Pharmacology…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Receptors, Purinergic P2X7, Rosaniline Dyes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: King Faisal University, Deanship of Scientific Research, King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Steatohepatitis links cholesterol-crystal injury to ATP-gated purinergic signaling, culminating in NF-κB/NLRP3 inflammasome activation and metabolic dysfunction. We posited that dissolving cholesterol burden while concurrently blocking P2X7 would reprogram lysosomal-purinergic crosstalk and outperform single-pathway therapy. In a streptozotocin-high-fat-diet diabetic rat model, hydroxypropyl-β-cyclodextrin (HPβCD; cholesterol efflux/crystal dissolution) combined with the P2X7 antagonist coomassie brilliant blue G-250 (CBB) improved glucose tolerance, fasting glycemia, and HOMA-IR beyond either monotherapy. In addition, this dual intervention lowered transaminases and inflammatory cytokines; reduced hepatic fibrosis and lipid overload; and restored lysosomal and insulin-signaling readouts. Mechanistically, dual treatment most effectively suppressed the P2X7-Panx1 axis, restored lysosomal integrity (increased LAMP1, decreased cathepsin-B), and curtailed NF-κB/NLRP3-GSDMD signaling, indicating disruption of the feed-forward loop connecting lysosomal injury with purinergic activation. Synergy at fixed in-vivo doses was formally quantified by HSA and Bliss, with the largest Bliss gains at purinergic-inflammasome nodes (P27RX, Panx1, NLRP3, p-AKT/AKT) and coherent effects at lysosomal biogenesis markers (LAMP1, TFEB). Integrative network analysis intersecting cholesterol-regulated genes with the P2RX7 interactome revealed an overlap enriched for IL-1β processing, pyroptosis, and lysosomal organization, nominating a high-connectivity P2RX7/Panx1-LAMP1/CTSB-NLRP3 module selectively reprogrammed by the combination. This work provides in-vivo evidence that simultaneously targeting cholesterol-crystal-driven lysosomal injury and ATP-gated P2X7 signaling yields mechanistic and therapeutic synergy, while linking systems-level network topology to multi-arm pharmacodynamics to define a reprogrammable lysosomal-purinergic module. Collectively, the data establish a mechanistically anchored, clinically plausible combination strategy for diabetes-associated steatohepatitis that surpasses single-pathway interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesReceptors, Purinergic P2X7Rosaniline DyesDiabetes Mellitus, ExperimentalPurinergic P2X Receptor AntagonistsLysosomes2-Hydroxypropyl-beta-cyclodextrinAnimalsMaleRatsDrug SynergismSignal TransductionLiverRats, Sprague-DawleyCholesterol

Stichwörter der Autor:innen

Cholesterol crystalsCoomassie brilliant blue G-250 (P2RX7 antagonist)Diabetes/insulin resistanceHydroxypropyl-β-cyclodextrin (HPβCD)Lysosomal–purinergic crosstalkNLRP3 inflammasome

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesReceptors, Purinergic P2X7Rosaniline DyesPurinergic P2X Receptor Antagonistscoomassie Brilliant Blue2-Hydroxypropyl-beta-cyclodextrinNlrp3 protein, ratCholesterol

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, 51452, Saudi Arabia; Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt. El…
  • Department of Anatomy and Histology, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia. Electronic address: M.elhefny@qu.edu.sa.
  • Department of Anatomy and Histology, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia. Electronic address: h.alsaykhan@qu.edu.sa.
  • Department of Pathology, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia. Electronic address: aaslom@qu.edu.sa.
  • Department of Pathology, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia; Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: mm.khodeir@qu.edu.sa.
  • Department of Pathology, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia. Electronic address: m.alorini@qu.edu.sa.

Förderung

  • King Faisal University
  • Deanship of Scientific Research, King Khalid University

Zitieren

APA

Elmorsy, E. A., Hatem, M. M., Alsaykhan, H., Alsalloom, A. A., Khodeir, M. M., Alorini, M., Hamad, R. S., Farrag, A. A., Ali, M. A. M., Alsoqih, N. S., Almansour, O., Alharbi, M. S., Alhowail, A. H., Ata, H. S., Elesawy, B. H., Sameh, A., & Saber, S. (2026). Reprogramming lysosomal–purinergic crosstalk governs the synergistic attenuation of NLRP3 inflammasome activation by cyclodextrin–P2X7 blockade in diabetic rats. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.178602

Vancouver

Elmorsy EA, Hatem MM, Alsaykhan H, Alsalloom AA, Khodeir MM, Alorini M, et al. Reprogramming lysosomal–purinergic crosstalk governs the synergistic attenuation of NLRP3 inflammasome activation by cyclodextrin–P2X7 blockade in diabetic rats. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.178602

BibTeX
@article{Elmorsy2026,
  author = {Elmorsy, Elsayed A and Hatem, Manal Mohamed and Alsaykhan, Hamad and Alsalloom, Abdulaziz A and Khodeir, Mostafa M and Alorini, Mohammed and Hamad, Rabab S and Farrag, Alshaimaa A and Ali, Mohamed A M and Alsoqih, Norah Suliman and Almansour, Omar and Alharbi, Mariam S and Alhowail, Ahmad H and Ata, Hesham Saad and Elesawy, Basem H and Sameh, Ahmed and Saber, Sameh},
  title = {Reprogramming lysosomal–purinergic crosstalk governs the synergistic attenuation of NLRP3 inflammasome activation by cyclodextrin–P2X7 blockade in diabetic rats},
  journal = {European Journal of Pharmacology},
  year = {2026},
  doi = {10.1016/j.ejphar.2026.178602}
}
Kostenlos starten →